东亚药业发行费用合计1.02亿元，其中，保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万 元。 据公司4月30日披露的《东兴证券股份有限公司关于浙江东亚药业股份有限公司2024年度募集资金存放 与使用情况专项核查报告》，根据中国证监会批复(证监许可〔2023〕1165号)，公司获准向不特定对象 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减变动幅度(%) | | 营业收入 | 190, 921, 213. 83 | 352. 582. 674. 10 | -45. 85 | | 归属于上市公司股东的净 | -6, 919, 576. 54 | 24, 039, 198. 04 | -128.78 | | 利润 | | | | | 归属于上市公司股东的扣 | -10, 505, 893. 27 | 20, 376, 579. 89 | -151. 56 | | 除非经常性损益的净利润 | | | | | 经营活动产生的现金流量 | -134, 527, 926. 86 | -97, 089, 771. 88 ...

Core Viewpoint - The company, Zhejiang Dongya Pharmaceutical Co., Ltd., reported a decrease in revenue and net profit for the year 2024, indicating challenges in its financial performance amidst a growing pharmaceutical market. Company Overview - Zhejiang Dongya Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the chemical pharmaceutical sector, which is positioned in the midstream of the overall pharmaceutical industry chain [6][19]. Market Overview - The global pharmaceutical market is projected to grow from $1,557.2 billion in 2023 to $1,638.7 billion in 2024, driven by factors such as population changes and advancements in artificial intelligence [7]. - China's pharmaceutical market is expected to expand from ¥179.77 billion in 2023 to ¥193.12 billion in 2024, with a forecast to exceed ¥2 trillion by 2025 [9]. Chemical Raw Material Market - The global raw material pharmaceutical market is anticipated to reach $226.1 billion by 2024, with a compound annual growth rate (CAGR) of 6% from 2023 to 2032 [10]. - China has become the world's largest producer and exporter of raw materials, with its production capacity increasing from approximately 9.3% in 2008 to about 30% in 2022 [11]. Company Financial Performance - For the reporting period, the company achieved revenue of ¥1,198.24 million, a decrease of 11.66% year-on-year, and a net profit attributable to shareholders of -¥100.66 million, down 183.02% year-on-year [27]. Product Positioning - The company has established a competitive advantage in the production of β-lactam antibiotics and quinolone antibiotics, with significant market presence in the production of key intermediates [17][19]. - The company is actively expanding its product offerings into the fields of cephalosporin antibiotics and is enhancing its production capabilities to meet downstream demand [18]. Business Strategy - The company is pursuing a strategy of integrating raw material and formulation production to enhance market opportunities and improve cost efficiency [12][19]. - The company has established a comprehensive supply chain management system to ensure stable supply and quality of raw materials [20]. Regulatory Environment - The Chinese government has implemented policies to support the development of innovative drugs and improve the overall quality of pharmaceuticals, which is expected to benefit leading companies in the raw material sector [11][14].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. faces significant challenges in 2024, with key financial indicators showing substantial changes, including a 183.02% decrease in net profit and a 43.16% increase in R&D expenses, which warrant close attention from investors [1]. Revenue - In 2024, the company achieved operating revenue of 1,198,238,535.39 yuan, a decrease of 11.66% from 1,356,448,097.16 yuan in the previous year, primarily due to fluctuating market demand [2]. - Quarterly revenue showed a downward trend, with figures of 352,582,674.10 yuan, 295,643,846.05 yuan, 314,792,722.32 yuan, and 235,219,292.92 yuan from Q1 to Q4, indicating pressure in market expansion [2]. Net Profit - The net profit attributable to shareholders was -100,660,051.84 yuan, down 183.02% from 121,249,399.50 yuan in 2023, attributed to reduced revenue, increased asset impairment losses, and higher R&D expenses [3]. - The company recognized inventory impairment losses due to operational management conditions and market changes, while the increase in R&D expenses was aimed at advancing the integrated development strategy of raw material drugs [3]. Deducted Net Profit - The deducted net profit was -98,408,150.01 yuan, a 191.03% decrease from 108,102,069.34 yuan in 2023, highlighting severe impacts on the core business's profitability [4]. - The minimal impact of non-recurring gains and losses on net profit indicates a need for improved competitiveness and cost control in core operations [4]. Earnings Per Share - Basic earnings per share were -0.90 yuan, down 184.11% from 1.07 yuan in 2023, reflecting a significant decline in the company's ability to create value for shareholders [5]. - The deducted earnings per share were -0.88 yuan, a 192.63% decrease from 0.95 yuan in 2023, consistent with the trends in deducted net profit, indicating a need for a reassessment of core business strategies [6]. Expenses - Overall expenses increased, with sales expenses rising by 11.29% to 15,387,268.47 yuan, management expenses up 24.14% to 170,269,093.67 yuan, and R&D expenses increasing by 43.16% to 117,016,684.56 yuan, reflecting pressure on cost control [7]. - Financial expenses decreased to -5,991,571.27 yuan from -7,909,974.75 yuan, indicating changes in cash flow management [7]. R&D Investment and Personnel - R&D investment reached 138,875,057.98 yuan, accounting for 11.59% of operating revenue, with a capitalized ratio of 15.74%, demonstrating a commitment to innovation [8]. - The R&D team consisted of 155 personnel, with a significant proportion being young and educated, although there may be a need for more high-end talent [9]. Cash Flow - The net cash flow from operating activities was -156,549,765.40 yuan, worsening from -84,061,904.21 yuan in the previous year, indicating increased cash outflow pressures [10]. - Investment activities resulted in a net cash flow of -90,159,116.32 yuan, while financing activities saw a significant decrease of 94.89% to 31,539,308.19 yuan, primarily due to the absence of large-scale fundraising in 2024 [10].

Core Insights - The company reported a net loss of approximately 101 million yuan for the fiscal year 2024, with total revenue of 1.198 billion yuan, reflecting a slight year-on-year decline [1] - The primary reason for the loss was asset impairment due to inventory write-downs and contract performance cost reductions, leading to a one-time asset impairment provision of 145 million yuan [1] - Despite poor financial performance, the company is advancing its capacity construction and R&D efforts, which are expected to enhance its core competitiveness in the long run [1][4] Financial Performance - The company’s revenue for 2024 was 1.198 billion yuan, a slight decrease compared to the previous year [1] - The first quarter of 2025 also showed continued losses, indicating ongoing financial challenges [1] - R&D investment reached a record high of 139 million yuan, accounting for 11.59% of total revenue, marking a 69.14% increase year-on-year [4] Product and Market Development - Key products maintained growth, with sales of the core product, Cefaclor, increasing by 28.24% for raw materials and 15.56% for intermediates in 2024 [2] - The company achieved a 11.55% increase in overseas revenue, totaling 209 million yuan, which supports its resilience against domestic healthcare cost controls [2] - The company received several international certifications for its raw materials, including WHO PQ certification for Levofloxacin, enhancing its global market competitiveness [3] Strategic Initiatives - The company is focused on a strategy of "forward extension and backward extension," emphasizing raw materials and expanding its product pipeline [4][5] - The completion of a convertible bond issuance raised nearly 700 million yuan, which is being used to expand production capacity and enhance product offerings [5] - The company is making significant progress in its formulation business, with multiple product registration applications submitted, indicating a robust pipeline for future growth [6]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-024 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 5 月 20 日 14 点 00 分 召开地点：浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 二楼会议室五 (五)网络投票的系统、起止日期和投票时间。 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-015 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届监事会第六次会议于 2025 年 4 月 28 日（星期一）在浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号二楼会议室五以现场表决的方式召开，本次会议通知已于 2025 年 4 月 18 日通过邮件 的方式送达公司全体监事。 本次会议由监事会主席徐菁女士主持，会议应参加表决监事 3 人，实际参加表决 监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规和 《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 会议由公司董事长池骋先生主持，监事、高管列席会议。本次会议的召集、召 开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各位董事认真审议，会议形成了如下决议： 浙江东亚药业股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届董事会第七次会议于 2025 年 4 月 28 日（星期一）在浙江省台州市临海市台州湾经济技术开发区东海第 五大道 21 号二楼会议室五以现场结合通讯的方式召开。本次会议通知于 2025 年 4 月 18 日以邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 （一）审议通过《关于 2024 年度总经理工作报告的议案》 表决情况：同意 7 票，反对 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东亚药业股份有限公司（以下简称"公司"）2024 年度拟不进行利润 分配，亦不进行资本公积金转增股本和其他形式的分配。 公司 2024 年度利润分配预案已经公司第四届董事会第七次会议和第四 届监事会第六次会议审议通过，尚需提交公司 2024 年年度股东大会审议批准。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下 简称"《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、利润分配预案内容 （一）利润分配预案的具体内容 经中汇会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表实现 归属于上市公司股东的净利润为人民币-10,066 ...

浙江东亚药业股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 www.zhcpa.cn Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 内部控制审计报告 中汇会审[2025]6493号 浙江东亚药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江东亚药业股份有限公司(以下简称东亚药业公司)2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，东亚药业公司于2024年12月31日按照《企业内部控制 ...

2024年度持续督导年度报告书 经中国证券监督管理委员会（以下简称"中国证监会"）"证监许可〔2023〕 1165 号文"核准，浙江东亚药业股份有限公司（以下简称"东亚药业"或"公司"） 于 2023 年向不特定对象发行可转换公司债券 690 万张，每张面值为人民币 100.00 元，募集资金总额为人民币 69,000 万元（以下简称"本次发行"）。东兴证券股份 有限公司（以下简称"东兴证券"或"保荐机构"）作为东亚药业本次发行的保荐 机构。 东兴证券股份有限公司 关于浙江东亚药业股份有限公司 东兴证券根据《证券发行上市保荐业务管理办法》、《上海证券交易所股票上市 规则》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关法规和规 范性文件的要求，对东亚药业进行了持续督导，现对 2024 年度持续督导工作汇报 如下： 一、持续督导工作情况 东兴证券作为东亚药业本次发行的保荐机构，针对东亚药业具体情况确定了持 续督导的内容和重点，通过日常沟通、定期回访、尽职调查等方式对东亚药业进行 了日常的持续督导，开展了以下相关工作： ...